Core Points - The actual utilization of foreign investment in China has exceeded the expected target for the 14th Five-Year Plan, reaching a cumulative total of 708.73 billion USD by the end of June 2023, six months ahead of the planned 700 billion USD target [1] - A total of 229,000 new foreign-funded enterprises have been established during this period, an increase of 25,000 compared to the 13th Five-Year Plan [1] - Foreign-funded enterprises contribute to one-third of the country's total imports and exports, one-fourth of industrial added value, and one-seventh of tax revenue, while also creating over 30 million jobs [1] Investment Environment - China has created a favorable environment for foreign investment by fully implementing the national treatment and negative list management system for foreign investment [2] - Manufacturing foreign investment restrictions have been lifted nationwide, and pilot programs for cloud computing, biotechnology, and wholly foreign-owned hospitals have been initiated in certain regions [2] - Over 1,100 pilot tasks have been carried out in 20 provinces and cities that are comprehensive pilot demonstration areas for expanding service industry openness [2] Policy Implementation - The "Foreign Investment 24 Measures" and the action plan for stabilizing foreign investment have been implemented, with 42 out of 59 measures already completed [2] - More than 500 regulations and documents have been formulated, revised, or abolished to optimize the legal and policy environment for foreign investment [2] - A robust service guarantee system has been established, with local governments forming specialized teams for foreign investment and holding over 30 roundtable meetings with foreign enterprises since 2023 to address various concerns [2]

Core Points - VERAXA Biotech AG is moving towards becoming a public company through a business combination with Voyager Acquisition Corp, with a registration statement filed with the SEC [1][2] - The business combination agreement values VERAXA at approximately $1.3 billion, with existing shareholders receiving around 130 million ordinary shares of the combined entity [3] - The expected pro forma equity value of the combined entity is approximately $1.64 billion, assuming a share price of $10.00 and no redemptions by Voyager's public shareholders [4] Transaction Overview - The boards of directors of both companies have unanimously approved the business combination, which is expected to close in Q4 2025, pending shareholder approval and customary closing conditions [5] - Upon closing, VERAXA anticipates access to approximately $253 million in cash held in trust by Voyager, before transaction costs [4] Company Information - VERAXA focuses on developing next-generation antibody-based therapeutics, including bispecific ADCs and T cell engagers, leveraging transformative technologies and rigorous quality principles [8] - The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory, known for its life science research [8] Advisors - Anne Martina Group is the sole M&A advisor for VERAXA, while Duane Morris LLP and Winston & Strawn LLP serve as legal counsel for VERAXA and Voyager, respectively [7]

Core Viewpoint - The company has conducted a self-examination regarding the trading activities of insiders and incentive recipients related to its 2025 restricted stock incentive plan, confirming no violations of insider trading regulations [1][2][3] Group 1: Incentive Plan Overview - The company announced its 2025 restricted stock incentive plan on June 28, 2025, and disclosed relevant proposals on the Shanghai Stock Exchange [1] - The incentive plan is governed by the "Management Measures for Equity Incentives of Listed Companies" and other relevant regulations [2] Group 2: Self-Examination Process - The company implemented necessary confidentiality measures and registered insiders and incentive recipients as per legal requirements [2] - A thorough investigation was conducted to verify if any insider or incentive recipient traded the company's stock within six months prior to the announcement of the incentive plan [2] Group 3: Findings and Conclusions - The examination revealed that no insider or incentive recipient engaged in trading the company's stock during the self-examination period [3] - All actions of the examined parties were found to be in compliance with the relevant regulations, confirming no insider trading occurred [3]

Group 1 - The core viewpoint of the news highlights the strong financial performance of BeiGene, with a significant increase in revenue and net profit for the fiscal year ending March 31, 2025 [1][2]. - As of July 15, BeiGene's stock opened at $268.0 per share, reflecting a 6.29% increase, with a total market capitalization of $31.745 billion [1]. - The company reported total revenue of $1.117 billion, representing a year-over-year growth of 48.64%, and a net profit attributable to shareholders of $1.27 million, which is a remarkable increase of 100.51% [1]. Group 2 - BeiGene is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2]. - The company has a comprehensive product portfolio, including six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2]. - Founded in Beijing in 2010, BeiGene went public on the NASDAQ Global Select Market in February 2016 and has built a global team of over 1,300 employees, covering research, clinical development, manufacturing, and commercialization [2].

Core Insights - The successful launch of the Tianzhou-9 cargo spacecraft marks a significant advancement in China's space exploration efforts, particularly in the study of human brain function in microgravity environments [1][2] - The mission involves 23 scientific experiments across various fields, including space life sciences, biotechnology, and materials science, with a total payload weight of 776.5 kilograms [1] Group 1: Research Focus - The research will utilize organ-on-a-chip technology to investigate the effects of microgravity on the human blood-brain barrier and muscle precursor cell migration [1][2] - The brain organ chip, developed by the Dalian Institute of Chemical Physics, integrates advanced biotechnologies to create a high-fidelity micro-brain model on a chip the size of a credit card [1][2] Group 2: Technological Advancements - The brain organ chip offers a more physiologically relevant environment compared to traditional cell cultures and animal models, featuring three-dimensional, dynamic, and visual characteristics [2] - This new model system aims to provide insights into the health risks associated with long-term space missions and potential interventions for astronauts [2] Group 3: Distinction Between Technologies - The brain organ chip focuses on simulating key structures and functions of human brain organs for disease modeling and drug development, while brain-machine interfaces emphasize interaction between brain signals and external devices [2]

智通财经7月14日电，利弗莫尔证券显示，湖南麦济生物技术股份有限公司-B向港交所提交上市申请 书，独家保荐人为中金公司。 湖南麦济生物技术股份有限公司-B香港IPO ...

据港交所文件：湖南麦济生物技术股份有限公司-B向港交所提交上市申请书。 ...

Group 1 - The 27th China International High-tech Achievements Fair (referred to as "High-tech Fair") will be held in Shenzhen from November 14 to 16, 2025, featuring a new "Technology-Strong County Exhibition Area" focused on modernizing county industrial chains and developing new productive forces [1][2] - The "Technology-Strong County Exhibition Area" will showcase advancements in cutting-edge fields such as artificial intelligence, big data, biomanufacturing, and new energy, aiming to accelerate the integration of technological innovations into county economies [1][2] - There are over 1,800 counties and county-level cities in China, with the county economy being a crucial engine for new urbanization, rural revitalization, and urban-rural integration, contributing significantly to the national economy [1][3] Group 2 - The High-tech Fair aims to present how county economies can leverage technological innovation for transformation, creating a new development landscape characterized by technology-driven growth and rural prosperity [2][3] - The event will gather over 5,000 leading technology enterprises, research institutions, universities, and investment organizations globally, promoting resource sharing, talent exchange, and collaborative innovation [2][4] - The fair will feature multiple exhibition areas, including biotechnology, artificial intelligence, smart manufacturing, and clean energy, showcasing a wide range of technological advancements and fostering international cooperation [3][4]

此次Danaher Beacon项目致力于开发基于脂质纳米颗粒递送的基因编辑创新疗法全流程工艺技术平台 .该项目将探索脂质纳米颗粒作为基因编辑递送系统在遗传性疾病治疗中的应用潜力 (2025年7月14日，上海)全球科学与技术的创新者丹纳赫宣布其旗下运营公司Cytiva思拓凡与正序生物开展战略合作，共同开发基于脂质纳 米颗粒递送系统的基因治疗创新工艺解决方案，以推动基因编辑技术在遗传性疾病治疗领域的突破。这也是丹纳赫第一次携手中国生物技 术企业开展Danaher Beacon合作。丹纳赫集团执行副总裁、Cytiva思拓凡首席执行官Chris Riley，丹纳赫中国首席科学官方焯、正序生物首 席执行官牟晓盾、Cytiva思拓凡中国总裁李蕾共同出席见证。 基因遗传性疾病是由基因突变引起的疾病，包括镰刀型贫血症、囊性纤维化、杜氏肌营养不良等数千种疾病[1]。绝大部分基因遗传性疾病 目前尚无药可医，而对于其中小部分病种，患者往往需要终生服药。近年来，在医学领域，基因编辑技术的进步为基因遗传疾病的治疗带 来了新的希望。正序生物开发的单碱基基因编辑技术具有高精度、低脱靶的特性，能够在庞大的基因组中精准、永久地改变单个碱基对 ...

Group 1 - The State-owned Assets Supervision and Administration Commission (SASAC) emphasizes the role of central enterprises in building a modern industrial system and a new development pattern through technological innovation, industrial control, and security support [1][2] - Central enterprises are encouraged to accelerate investment in strategic emerging industries, with a projected investment of 2.7 trillion yuan in 2024, representing a year-on-year increase of 21.8% and surpassing 40% of total investment for the first time [2] - The revenue from strategic emerging industries is expected to exceed 1.1 trillion yuan, accounting for nearly 30% of total revenue [2] Group 2 - The SASAC plans to enhance the development mechanism for strategic emerging and future industries, allowing for loss exemption periods for enterprises or projects engaged in these sectors [3]